Every Form 4 that Cellebrite DI Ltd. (CLBT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLBT filings page.
Cellebrite DI Ltd. (CLBT) Chief Financial Officer David Barter sold 12,134 ordinary shares on October 16, 2026, at a weighted average price of $11.2139 per share. The shares had been granted as restricted stock units on July 7, 2025, and their disposition was associated with tax obligations tied to vesting. Barter directly held 322,085 shares after the sale. No Rule 10b5-1 plan is reported.
Cellebrite DI Ltd. director Ryusuke Utsumi received an award of 15,190 restricted share units on September 17, 2026. The units are scheduled to vest on September 17, 2027; each represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings following the transaction were 66,586 ordinary shares.
Cellebrite DI Ltd. director Yonatan Domnitz received an award of 15,190 restricted share units on September 17, 2026. The units are scheduled to vest on September 17, 2027, and each represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings following the transaction were 86,586 ordinary shares.
Cellebrite DI Ltd. director Adam Clammer received an award of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs vest on September 17, 2027, and each represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings after the award were 86,586 ordinary shares.
Reported indirect holdings included 13,861,007 ordinary shares held by TWC Tech Holdings II, LLC, including 1,500,000 shares subject to transfer restrictions pending performance-based vesting conditions, and 375,000 shares each held by Long Term Trust and Joint Revocable Trust. Clammer may be deemed to share beneficial ownership of TWC-held shares as a managing member of its ultimate controlling entity; he disclaims beneficial ownership except to the extent of his pecuniary interest.
Cellebrite DI Ltd. (CLBT) Chief Executive Officer and director Ramji Shiven acquired an award of 38,505 restricted share units on September 24, 2026. Each unit represents a contingent right to receive one ordinary share upon settlement, and the reported direct position following the award was 462,055 ordinary shares. The units vest in installments beginning May 4, 2027; no Rule 10b5-1 plan is reported.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Van Buren Brandon reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Brandon Van Buren received an equity compensation award in the form of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU delivering one Ordinary Share upon settlement, increasing his directly held Ordinary Shares to 50,744.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Richardson Troy reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Troy Richardson received a grant of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU settling into one Ordinary Share. Following this award, Richardson directly holds 36,164 Ordinary Shares. The grant carries a stated price of $0.00 per share, indicating a compensation-related equity award rather than a market purchase.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Gruber Dafna reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Dafna Gruber received an equity award of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, each settling into one ordinary share, bringing her directly held position to 43,109 ordinary shares.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Baudot-Trajtenberg Nadine reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Nadine Baudot-Trajtenberg received an equity award of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU settling into one Ordinary Share upon vesting. Following this award, she holds 50,744 Ordinary Shares directly.
Cellebrite DI Ltd. (CLBT) reported that advisor Thomas E. Hogan sold ordinary shares in a Form 4 filing. On August 25, 2026, he sold 25,299 ordinary shares at a weighted average price of $11.2934 per share in open-market or private transactions, at prices ranging from $11.205 to $11.36. The filing states these shares had been granted as restricted stock units (RSUs) on February 10, 2026 and that the disposition was associated with the reporting person’s tax obligations arising from RSU vesting. Following the sale, Hogan directly held 765,249 ordinary shares of Cellebrite.
Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold ordinary shares in a scheduled transaction. On August 24, 2026, he sold 4,323 shares of ordinary shares at a weighted average price of $11.3605 per share, with individual trade prices ranging from $11.06 to $11.76. The sale was effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, and Gee now directly holds 135,281 shares of Cellebrite stock.
Cellebrite DI Ltd. (CLBT) reported that Global Chief Revenue Officer Marcus Jewell sold 12,562 ordinary shares on August 21, 2026. The transaction was executed at a weighted average price of $11.2416 per share, from multiple trades between $11.16 and $11.30. According to the disclosure, these shares were originally granted as restricted stock units on November 15, 2023, and the disposition is associated with Jewell’s tax obligations related to RSU vesting. Following the sale, he directly holds 427,128 ordinary shares of Cellebrite.
Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold 2,198 ordinary shares on August 21, 2026 in an open-market transaction at a weighted average price of $11.2416 per share, with individual trades ranging from $11.16 to $11.30. The shares sold were originally granted as restricted stock units (RSUs) on May 20, 2024, and the disposition is associated with the reporting person’s tax obligations upon vesting of those RSUs. Following this transaction, Gee directly holds 139,604 ordinary shares of Cellebrite DI Ltd.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan reported equity compensation and related share withholding. On August 11, 2026, 339,484 ordinary shares were delivered to him upon certification that performance conditions for awards granted on September 19, 2025 were met. On August 12, 2026, 139,713 shares from this vesting were withheld and disposed of to cover his tax obligations at a weighted average price of $15.3861 per share, with individual trades between $15.06 and $15.73. The transactions are reported as directly owned and are not affirmed as executed under a Rule 10b5-1 trading plan.
Cellebrite DI Ltd. executive Jewell Marcus, Global Chief Revenue Officer, reported selling 411 ordinary shares of Cellebrite DI Ltd. on August 12, 2026 at a weighted average price of $16.0678 per share. A footnote explains the shares were originally granted as RSUs on February 11, 2025 and that the disposition is associated with tax obligations arising from the RSU vesting, effectively a sale to cover taxes. After this transaction, Marcus directly holds 439,690 ordinary shares. The transaction was not marked as conducted under a Rule 10b5-1 trading plan.
Cellebrite DI Ltd. executive David Nicholas Gee, Chief Marketing Officer, reported a sale of 230 ordinary shares of Cellebrite on August 12, 2026. The shares relate to restricted stock units granted on February 11, 2025, and the disposition is associated with the reporting person's tax obligations upon vesting of those RSUs. The weighted average sale price was $16.0678 per share, from multiple trades between $16.0086 and $16.08. Following this transaction, Gee directly holds 141,802 ordinary shares of Cellebrite.
Cellebrite DI Ltd. Chief Financial Officer David Barter reported an open-market sale of 41,734 ordinary shares at a weighted average price of $16.3756 per share. The filing states the shares were originally granted as RSUs on July 7, 2025 and that the disposition is associated with tax obligations related to their vesting.
After the transaction, Barter directly holds 334,219 ordinary shares. The price reflects multiple trades between $16.21 and $16.62 per share.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan reported an open-market sale of 103,188 ordinary shares. The shares were originally granted as restricted stock units on September 19, 2025, and the disposition is associated with tax obligations arising from the RSU vesting.
The shares were sold at a weighted average price of $15.7566 per share, in multiple trades between $15.44 and $15.97. Following this transaction, Hogan directly holds 590,777 ordinary shares of Cellebrite DI Ltd.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported net open-market sales of 5,673 ordinary shares of Cellebrite (CLBT). The sales occurred on May 21, 2026 at weighted average prices of about $13.15 and $13.10 per share, within disclosed ranges of $13.00–$13.30 and $12.98–$13.32.
According to the footnotes, the shares sold were originally granted as restricted stock units on May 20, 2024, and the dispositions are associated with his tax obligations upon vesting. After these transactions, Gee directly holds 142,032 ordinary shares of Cellebrite. The filing states that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Gee on November 18, 2025, indicating they were scheduled in advance.
Cellebrite DI Ltd. Global Chief Revenue Officer Marcus Jewell reported an open-market sale of 12,658 ordinary shares at a weighted average price of $12.7711 per share. The shares were originally granted as RSUs, and the disposition is associated with tax obligations from their vesting. Following the sale, Jewell directly holds 440,101 ordinary shares.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported a small open-market sale of company shares linked to tax obligations from vested equity awards. He sold 228 ordinary shares at a weighted average price of $13.01 per share, with individual trades ranging from $12.84 to $13.175. These shares originated from restricted stock units granted on February 11, 2025 and were sold to cover associated tax liabilities. After the transaction, Gee directly owned 147,705 ordinary shares, indicating that the sale represented only a minor portion of his overall holdings.
Cellebrite DI Ltd. Global Chief Revenue Officer Marcus Jewell reported an open-market sale of 383 ordinary shares at a weighted average price of $13.01 per share. The footnotes explain the disposition is associated with tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Jewell directly holds 452,759 ordinary shares.
Ramji Shiven reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. reported that President Products & Tech Ramji Shiven received a compensation grant of 423,550 restricted share units (RSUs), each representing one ordinary share when settled. Following this award, he holds 423,550 ordinary shares directly.
The RSUs vest over time: 105,898 vest on May 4, 2027, and 26,471 additional RSUs vest every three months through May 4, 2030, encouraging long-term retention and performance alignment.